Agios Establishes Proof-of-Concept for Mitapivat in Non-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. SPY
2. ORCL
3. USO
4. LLY
5. KKR
6. DAVA
7. PSKY
8. MONC:IM
9. PTON
10. NYXH

Go back to Agios Establishes Proof-of-Concept for Mitapivat in Non-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results
AGIOS PHARM (NASDAQ: AGIO) Delayed: 33.95 --0 (-0%)
Previous Close $33.95    52 Week High $71.49 
Open $33.95    52 Week Low $33.50 
Day High $33.95    P/E N/A 
Day Low $33.95    EPS $-1.18 
Volume 371